Literature DB >> 551199

Rift Valley fever vaccine--antibody and immune response in cattle to a live and an inactivated vaccine.

B J Barnard.   

Abstract

In a study of the response in cattle to a live and an inactivated Rift Valley fever (RVF) vaccine prepared from cell cultures infected with RVF virus, the effects of varying doses and combinations of these vaccines were compared. The antibody response to a primary injection of either vaccines was poor when measured by the serum virus neutralization test (SVN) and the haemagglutination-inhibition test (HI) but a booster dose of inactivated vaccine evoked a good anamnestic response in cattle previously injected with either of these vaccines. Cattle vaccinated with the live vaccine but negative to the SVN or the HI for RVF were immune when challenged with a virulent RVF virus isolated from a cow during 1974.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 551199

Source DB:  PubMed          Journal:  J S Afr Vet Assoc        ISSN: 1019-9128            Impact factor:   1.474


  21 in total

1.  Creation of a nonspreading Rift Valley fever virus.

Authors:  Jeroen Kortekaas; Nadia Oreshkova; Viviana Cobos-Jiménez; Rianka P M Vloet; Christiaan A Potgieter; Rob J M Moormann
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Rift Valley fever virus structural and nonstructural proteins: recombinant protein expression and immunoreactivity against antisera from sheep.

Authors:  Bonto Faburay; William Wilson; D Scott McVey; Barbara S Drolet; Hana Weingartl; Daniel Madden; Alan Young; Wenjun Ma; Juergen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2013-08-20       Impact factor: 2.133

3.  Evaluation of an Indirect Enzyme-Linked Immunosorbent Assay Based on Recombinant Baculovirus-Expressed Rift Valley Fever Virus Nucleoprotein as the Diagnostic Antigen.

Authors:  Bonto Faburay; William C Wilson; Arss Secka; Barbara Drolet; D Scott McVey; Juergen A Richt
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

4.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

5.  Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging.

Authors:  Paul J Wichgers Schreur; Nadia Oreshkova; Rob J M Moormann; Jeroen Kortekaas
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

Review 6.  Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.

Authors:  Michele Bouloy; Ramon Flick
Journal:  Antiviral Res       Date:  2009-08-12       Impact factor: 5.970

7.  Molecular epidemiology of Rift Valley fever virus.

Authors:  Antoinette A Grobbelaar; Jacqueline Weyer; Patricia A Leman; Alan Kemp; Janusz T Paweska; Robert Swanepoel
Journal:  Emerg Infect Dis       Date:  2011-12       Impact factor: 6.883

8.  Rift Valley Fever outbreaks in Mauritania and related environmental conditions.

Authors:  Cyril Caminade; Jacques A Ndione; Mawlouth Diallo; Dave A MacLeod; Ousmane Faye; Yamar Ba; Ibrahima Dia; Andrew P Morse
Journal:  Int J Environ Res Public Health       Date:  2014-01-09       Impact factor: 3.390

9.  Randomized controlled field trial to assess the immunogenicity and safety of rift valley fever clone 13 vaccine in livestock.

Authors:  M Kariuki Njenga; Leonard Njagi; S Mwangi Thumbi; Samuel Kahariri; Jane Githinji; Eunice Omondi; Amy Baden; Mbabu Murithi; Janusz Paweska; Peter M Ithondeka; Kisa J Ngeiywa; Baptiste Dungu; Meritxell Donadeu; Peninah M Munyua
Journal:  PLoS Negl Trop Dis       Date:  2015-03-10

10.  A single vaccination with an improved nonspreading Rift Valley fever virus vaccine provides sterile immunity in lambs.

Authors:  Nadia Oreshkova; Lucien van Keulen; Jet Kant; Rob J M Moormann; Jeroen Kortekaas
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.